JS
James Stearns
Non Executive Director at Blueberry Therapeutics Ltd
United Kingdom
Overview
James Stearns is currently serving as the Chief Investment Officer (International) at China Medical System Holdings Ltd, where he oversees investments in Biotech companies at Series A and Seed stages. With a distinguished career, he has held significant roles such as Non-Executive Director at Blueberry Therapeutics Ltd and Neurelis, Inc., showcasing expertise in strategic leadership and governance.
Work Experience
Chief Investment Officer (International)
2021 - Current
Non Executive Director
2023
Neurelis is a specialty pharmaceutical company providing a highly differentiated approach to target unmet medical needs.
Raised $206,081,950.00 from Philos & Partners, LYZZ Capital, Decheng Capital, Cormorant Asset Management and HBM Healthcare Investments.
Non Executive Director
2023
Board Observer
2023
Non Executive Director
2022
Investment Committee
2021
Non Executive Director
2021
Board Observer
2022 - 2024
Non Executive Director
2022 - 2024
Non Executive Director
2023 - 2024